![Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/20r02799T1.gif)
Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com
![Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/20r02799F1.gif)
Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com
![Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnpjschz.2015.39/MediaObjects/41537_2015_Article_BFnpjschz201539_Fig1_HTML.jpg)
Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia
![Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/20r02799T2.gif)